SEC Form 4 · accession 0001209191-18-057789
Denali Therapeutics Inc. · DNLI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jennifer E. Cook
Director
Period of report
Nov 6, 2018
Accepted (ET)
Nov 8, 2018 · 5:37 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001714899
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $17.08 | Nov 6, 2018 | A | 50,044 | A | — | Nov 5, 2028 | Common Stock | 50,044 | 50,044 | D |
Explanation of responses
- F125% of the shares subject to the option shall vest on November 6, 2019, and an additional 1/48 of the shares subject to the option vest each month thereafter.